# Nutriband Inc. (NTRB) Raises $1.75 Million from Warrant Exercises for FDA Approval Push

- URL: https://stocks.freetheai.org/news/nutriband-inc-ntrb-raises-1-75-million-from-warrant-exercises-for-fda-approval-1125d5
- Published: 2026-10-13T12:00:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:NTRB](https://stocks.freetheai.org/symbols/NASDAQ-NTRB)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Nutriband Inc. (NTRB) brought in over $1.75 million in gross proceeds following the exercise of 272,671 warrants. Holders exercised the warrants at a strike price of $6.43 per share prior to their expiration on September 30. With these exercises completed, the pharmaceutical company no longer has any tradeable warrants remaining.

The cash infusion will support Nutriband Inc.'s lead drug candidate, AVERSA Fentanyl, which uses proprietary technology designed to prevent opioid abuse, misuse, and accidental exposure by integrating aversive ingredients into patches. Funding will be directed toward finishing the remaining clinical development phases and preparing a New Drug Application for submission to the U.S. Food and Drug Administration.

Investors will monitor regulatory progress and clinical milestones as Nutriband Inc. advances toward potential FDA marketing authorization. The company estimates that its abuse-deterrent patch could achieve peak annual U.S. revenues between $80 million and $200 million if approved. Share prices fell 12.03% to $5.85 following the update.

## Key points

- Nutriband Inc. (NTRB) generated $1,753,274.53 in gross proceeds from the exercise of 272,671 warrants at $6.43 per share.
- The company no longer has any tradeable warrants active following their expiration on September 30.
- Proceeds will fund remaining clinical work and an FDA New Drug Application for AVERSA Fentanyl.
- AVERSA Fentanyl is an abuse-deterrent patch estimated to have potential peak U.S. annual sales of $80 million to $200 million.

## Questions and answers

### How much money did Nutriband Inc. raise from its warrant exercises?

Nutriband Inc. received $1,753,274.53 in gross proceeds from 272,671 warrants exercised at a strike price of $6.43 per share.

### How will Nutriband Inc. use the proceeds from the warrant exercise?

The funds will primarily support the remaining clinical development of AVERSA Fentanyl and the submission of a New Drug Application to the U.S. FDA for marketing approval.

### Does Nutriband Inc. have any remaining tradeable warrants?

No, Nutriband Inc. has no remaining tradeable warrants following their expiration on September 30.